NTRR (Neutra) EBITDA Margin %: -43.75% (As of Apr. 2024)

What is Neutra EBITDA Margin %?

Neutra NTRR +100.00% EBITDA Margin % is -43.75% as of Apr. 2024.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Neutra's EBITDA for the three months ended in Apr. 2024 was $-0.01 Mil. Neutra's Revenue for the three months ended in Apr. 2024 was $0.03 Mil. Therefore, Neutra's EBITDA margin for the quarter that ended in Apr. 2024 was -43.75%.

Neutra (OTCPK:NTRR) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Neutra EBITDA Margin % Related Terms

Neutra EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Neutra's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neutra EBITDA Margin % Chart

Neutra Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

EBITDA Margin %

Get a 7-Day Free Trial

-5,916.67

-3,870.00

-538.04

-613.24

-452.50

Neutra Quarterly Data
	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24
EBITDA Margin %	Get a 7-Day Free Trial															-850.00	-1,475.00	-4,400.00	-96.43	-43.75

NTRR vs NXEN, PNXP, PLSH: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Neutra's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neutra EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neutra's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Neutra's EBITDA Margin % falls into.

Save Embed

Neutra EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Neutra's EBITDA Margin % for the fiscal year that ended in Jan. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Jan. 2024 )	/	Revenue (A: Jan. 2024 )
	=	-0.181	/	0.04
	=	-452.50 %

Neutra's EBITDA Margin % for the quarter that ended in Apr. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Apr. 2024 )	/	Revenue (Q: Apr. 2024 )
	=	-0.014	/	0.032
	=	-43.75 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -43.75% mean?

Neutra (NTRR) has a EBITDA Margin % of -43.75% as of Apr. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neutra and its competitors.

Is Neutra's EBITDA Margin % too high?

Neutra's current EBITDA Margin % is -43.75%.

How does Neutra's EBITDA Margin % compare to NXEN and PNXP?

Neutra's EBITDA Margin % of -43.75% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Drug Manufacturers company?

The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neutra and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neutra's current EBITDA Margin % is -43.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Neutra stock overvalued right now?

Neutra (NTRR) has a current EBITDA Margin % of -43.75%. The current EBITDA Margin % is -43.75%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Neutra (NTRR), the current EBITDA Margin % is -43.75% as of Apr. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neutra Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies NXEN PNXP PLSH GCAN KOAN THCT BSPK ABTI KAYS CBDY ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA

Address 2500 CityWest Boulevard, Suite 150-161, Houston, TX, USA, 77042

Website https://www.neutrainc.com

Neutra Corp to market and participate in the nutraceutical space by bringing products derived from all natural and organic origins. Along with participating in the actual nutraceutical products, It plan to research and bring new technology to the nutraceutical space. Nutraceutical natural medicine is an alternative system that focuses on natural remedies and the body's vital ability to heal and maintain itself.